Baxter International (BAX) to Release Quarterly Earnings on Thursday

Baxter International (NYSE:BAX) will be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect Baxter International to post earnings of $0.61 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.02. Baxter International had a net margin of 17.77% and a return on equity of 19.49%. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.81 billion. During the same period in the previous year, the company earned $0.88 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, analysts expect Baxter International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Baxter International Stock Down 0.2 %

BAX opened at $40.93 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The firm has a 50 day moving average price of $41.86 and a 200-day moving average price of $38.50. Baxter International has a twelve month low of $31.01 and a twelve month high of $50.21. The stock has a market capitalization of $20.79 billion, a price-to-earnings ratio of 7.84, a PEG ratio of 2.17 and a beta of 0.62.

Baxter International Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, April 1st. Shareholders of record on Friday, March 1st were given a $0.29 dividend. The ex-dividend date was Thursday, February 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 2.83%. Baxter International’s payout ratio is currently 22.22%.

Wall Street Analysts Forecast Growth

BAX has been the topic of several research analyst reports. Bank of America boosted their target price on shares of Baxter International from $42.00 to $45.00 and gave the stock a “neutral” rating in a report on Tuesday, March 5th. Citigroup upped their price target on shares of Baxter International from $41.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. upped their price target on shares of Baxter International from $38.00 to $44.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Barclays upped their price target on shares of Baxter International from $52.00 to $54.00 and gave the company an “overweight” rating in a research note on Monday, February 12th. Finally, UBS Group decreased their price target on shares of Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 6th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $46.30.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.